CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-07). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2374 · Search date 2026-08-07 · Methodology v0.7

Lemon juice and citric acid,
does it really help with Prevention of two-year recurrent idiopathic calcium oxalate stones?

30-Second Summary
D
Evidence Grade D · 34 · Safety caution
Daily 120 mL lemon juice did not significantly reduce two-year stone recurrence, and adherence fell below half.
Heartburn and epigastric pain were more frequent, and adverse-event withdrawal was 6.0% versus 2.9%. Dental acid erosion and gastrointestinal symptoms should be considered with prolonged use.
What the
research shows
The grade is D. In a single-center PROBE randomized trial, two-year stone recurrence was 21/100 (21.0%) with lemon juice plus standard diet versus 32/103 (31.1%) with standard diet alone, HR 0.62 (95% CI 0.35 to 1.07), P=.089. The primary outcome failed, although the interval still leaves possible benefit.
What the
ads claim
The compositional fact that lemons contain citric acid is different from clinical prevention of long-term recurrence. The trial found no between-group increase in urinary citrate and missed its two-year recurrence primary outcome.
*

Useful facts when choosing a product

  • The trial used 60 mL fresh lemon juice twice daily.
  • Expected citric-acid intake was 6 g or 92 mEq daily.
  • Controls received the same diet and 2 to 2.5 L daily water advice.
  • Overall attrition was 45/203 (22.2%); separately, lemon-juice adherence declined from 79% at six months to 68% at one year and 48% at two years.
Gap Measurement · Verdict 2374 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

This single-center Bergamo trial randomized 203 participants and analyzed all by intention to treat. Two-year completion was 74/100 versus 84/103; withdrawal was 26.0% versus 18.4%, or 45/203 (22.2%) overall. Adherence fell from 79% at six months to 68% at one year and 48% at two years. No independent replication RCT was confirmed. The source states: “This study received no funding.”

02

Why this is classified as D (34)

A human randomized trial exists, so judgment is not deferred. Its prespecified two-year recurrence outcome was null, it remains a single trial, and 22.2% did not complete two-year follow-up, giving D with 34 points.

Counterpoint. The HR lower bound of 0.35 leaves substantial benefit possible. The 20-point sample-size assumption was not treated as a clinical exclusion boundary.

Rejudgment record. Cross-check applied — Dose, diet control, composite recurrence definition, two-year events, withdrawal, and adherence were checked

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prevention of two-year stone recurrenceDThe prespecified primary analysis had P=.089.
Prevention of one-year stone recurrenceCA post hoc exploratory analysis was positive.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Single-center prospective randomized open blinded-endpoint trial24This study received no fundingPrimary outcome: time to stone recurrence over two years21/100 (21.0%) vs 32/103 (31.1%); HR 0.62 (95% CI 0.35 to 1.07), P=.089Only direct randomized evidence
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-07).

Ruggenenti P, Caruso MR, Cortinovis M, et al. Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: a PROBE trial. EClinicalMedicine. 2021;43:101227. PMID: 34977512. DOI: 10.1016/j.eclinm.2021.101227.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-07 · Corrections: none

Cite this verdict

Lemon juice and citric acid x prevention of urinary-stone recurrence Evidence Grade D card
[Chamgap] Lemon juice and citric acid x prevention of urinary-stone recurrence — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/lemon-juice-calcium-oxalate-stone-recurrence/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.